{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT03486067","nct_id":"NCT03486067","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03486067. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"Administration of CC-93269","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2025-03-18","type":"ACTUAL"},"conditions":["Multiple Myeloma"],"enrollment":{"count":183,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"CC-93269","otherNames":["Alnuctamab"],"type":"DRUG"}],"last_update":"2025-04-17","lead_sponsor":"Celgene","official_title":"A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma","overall_status":"TERMINATED","phases":["PHASE1"],"primary_completion_date":{"date":"2025-03-18","type":"ACTUAL"},"primary_outcomes":[{"measure":"Adverse Events (AEs)","timeFrame":"Up to approximately 63 months"},{"measure":"Dose Limiting Toxicity (DLT)","timeFrame":"Up to 60 months"},{"measure":"Non-Tolerated Dose (NTD)","timeFrame":"Up to 60 months"},{"measure":"Maximum Tolerated Dose (MTD)","timeFrame":"Up to 60 months"}],"references":[],"start_date":{"date":"2018-04-03","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma","url":"https://clinicaltrials.gov/study/NCT03486067"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03486067"}